CCL5
CCR5受体拮抗剂
马拉维洛克
癌症研究
血管生成
趋化因子
背景(考古学)
医学
免疫学
趋化因子受体
生物
T细胞
炎症
免疫系统
白细胞介素2受体
古生物学
人类免疫缺陷病毒(HIV)
作者
Donatella Aldinucci,Cinzia Borghese,Naike Casagrande
出处
期刊:Cancers
[Multidisciplinary Digital Publishing Institute]
日期:2020-07-02
卷期号:12 (7): 1765-1765
被引量:404
标识
DOI:10.3390/cancers12071765
摘要
Tumor cells can "hijack" chemokine networks to support tumor progression. In this context, the C-C chemokine ligand 5/C-C chemokine receptor type 5 (CCL5/CCR5) axis is gaining increasing attention, since abnormal expression and activity of CCL5 and its receptor CCR5 have been found in hematological malignancies and solid tumors. Numerous preclinical in vitro and in vivo studies have shown a key role of the CCL5/CCR5 axis in cancer, and thus provided the rationale for clinical trials using the repurposed drug maraviroc, a CCR5 antagonist used to treat HIV/AIDS. This review summarizes current knowledge on the role of the CCL5/CCR5 axis in cancer. First, it describes the involvement of the CCL5/CCR5 axis in cancer progression, including autocrine and paracrine tumor growth, ECM (extracellular matrix) remodeling and migration, cancer stem cell expansion, DNA damage repair, metabolic reprogramming, and angiogenesis. Then, it focuses on individual hematological and solid tumors in which CCL5 and CCR5 have been studied preclinically. Finally, it discusses clinical trials of strategies to counteract the CCL5/CCR5 axis in different cancers using maraviroc or therapeutic monoclonal antibodies.
科研通智能强力驱动
Strongly Powered by AbleSci AI